<br />
RHEUMATOLOGY<br />
EULAR supplement • emjreviews.com<br />
INSIDE<br />
The Evolving Landscape of Rheumatology:<br />
Biosimilarity and Extrapolation<br />
THE EVOLVING LANDSCAPE OF RHEUMATOLOGY:<br />
BIOSIMILARITY AND EXTRAPOLATION<br />
This symposium took place on 9th June 2016, as part of the<br />
European League Against Rheumatism (EULAR) Congress 2016<br />
in London, UK<br />
Chairperson<br />
Peter Taylor1<br />
Speakers<br />
Emily Shacter,2 Craig Leonardi,3 Peter Taylor1<br />
1. Kennedy Institute of Rheumatology, Oxford University, Oxford, UK<br />
2. ThinkFDA, LLC, Washington DC, USA<br />
3. Department of Dermatology, St Louis University, Missouri, USA<br />
Disclosure: Prof Peter Taylor has received consulting fees, research or institutional support, and educational<br />
grants from Roche, UCB, Glaxo SmithKline, Bristol-Mye<a title="EMJ Rheumatol. 2016 Suppl 14 page 1" href="http://viewer.zmags.com/publication/c973dafd?page=1"> RHEUMATOLOGY EULAR supplement • emjreviews.com </a>
<a title="EMJ Rheumatol. 2016 Suppl 14 page 2" href="http://viewer.zmags.com/publication/c973dafd?page=2"> THE EVOLVING LANDSCAPE OF RHEUMATOLOGY: </a>
<a title="EMJ Rheumatol. 2016 Suppl 14 page 3" href="http://viewer.zmags.com/publication/c973dafd?page=3"> Laying the Foundation: Analytical and Functional </a>
<a title="EMJ Rheumatol. 2016 Suppl 14 page 4" href="http://viewer.zmags.com/publication/c973dafd?page=4"> inflammatory bowel disease (IBD), then the FDA exp</a>
<a title="EMJ Rheumatol. 2016 Suppl 14 page 5" href="http://viewer.zmags.com/publication/c973dafd?page=5"> Difference in response between infliximab and plac</a>
<a title="EMJ Rheumatol. 2016 Suppl 14 page 6" href="http://viewer.zmags.com/publication/c973dafd?page=6"> disease modifying anti-rheumatic drugs (DMARDs) a</a>
<a title="EMJ Rheumatol. 2016 Suppl 14 page 7" href="http://viewer.zmags.com/publication/c973dafd?page=7"> In conclusion, the totality-of-the-evidence t</a>
<a title="EMJ Rheumatol. 2016 Suppl 14 page 8" href="http://viewer.zmags.com/publication/c973dafd?page=8"> starting biosimilars should be made in partnershi</a>
<a title="EMJ Rheumatol. 2016 Suppl 14 page 9" href="http://viewer.zmags.com/publication/c973dafd?page=9"> Given the discussion here of the importance and </a>
<a title="EMJ Rheumatol. 2016 Suppl 14 page 10" href="http://viewer.zmags.com/publication/c973dafd?page=10"> Pharmacokinetics and Safety of GP2015, a Proposed</a>
<a title="EMJ Rheumatol. 2016 Suppl 14 page 11" href="http://viewer.zmags.com/publication/c973dafd?page=11"> iosimilar, and Etanercept Originator </a>
<a title="EMJ Rheumatol. 2016 Suppl 14 page 12" href="http://viewer.zmags.com/publication/c973dafd?page=12"> Pharmacokinetics and Safety of GP2015, a Proposed</a>
<a title="EMJ Rheumatol. 2016 Suppl 14 page 13" href="http://viewer.zmags.com/publication/c973dafd?page=13"> t Biosimilar, Administered </a>